Kennedy Capital Management LLC Raises Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Kennedy Capital Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 25.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,013 shares of the biopharmaceutical company's stock after purchasing an additional 16,603 shares during the quarter. Kennedy Capital Management LLC's holdings in Gilead Sciences were worth $7,668,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the company. XTX Topco Ltd bought a new position in Gilead Sciences in the third quarter valued at about $581,000. Coldstream Capital Management Inc. increased its holdings in shares of Gilead Sciences by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company's stock worth $1,932,000 after purchasing an additional 2,043 shares during the last quarter. TD Private Client Wealth LLC raised its stake in Gilead Sciences by 10.6% during the third quarter. TD Private Client Wealth LLC now owns 57,509 shares of the biopharmaceutical company's stock valued at $4,822,000 after purchasing an additional 5,497 shares in the last quarter. Rehmann Capital Advisory Group grew its position in Gilead Sciences by 3.6% in the third quarter. Rehmann Capital Advisory Group now owns 9,626 shares of the biopharmaceutical company's stock worth $807,000 after acquiring an additional 333 shares in the last quarter. Finally, Westside Investment Management Inc. increased its position in shares of Gilead Sciences by 3.5% during the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock valued at $2,249,000 after purchasing an additional 917 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Remove Ads

Insider Activity

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 1.1 %

Gilead Sciences stock traded down $1.13 during trading on Tuesday, reaching $105.37. 3,343,203 shares of the company were exchanged, compared to its average volume of 7,480,585. The stock's 50 day simple moving average is $108.48 and its two-hundred day simple moving average is $97.05. The company has a market capitalization of $131.20 billion, a P/E ratio of 284.78, a PEG ratio of 0.71 and a beta of 0.32. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were paid a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 3.00%. The ex-dividend date was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is presently 854.05%.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Oppenheimer increased their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Morgan Stanley boosted their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a report on Tuesday, March 11th. Piper Sandler lifted their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Finally, BMO Capital Markets increased their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.